ECOG 0 4 0 4 B-clinical_variable
performance 5 16 5 16 I-clinical_variable
status 17 23 17 23 I-clinical_variable
greater 24 31 24 31 O
than 32 36 32 36 O
or 37 39 37 39 O
equal 40 45 40 45 O
to 46 48 46 48 O
2 49 50 49 50 B-lower_bound

Failed 0 6 51 57 O
prior 7 12 58 63 B-treatment
therapy 13 20 64 71 I-treatment
with 21 25 72 76 I-treatment
a 26 27 77 78 I-treatment
secondary 28 37 79 88 I-treatment
hormone 38 45 89 96 I-treatment
( 46 47 97 98 O
e.g. 47 51 98 102 O
enzalutamide 52 64 103 115 B-treatment
, 64 65 115 116 O
abiraterone 66 77 117 128 B-treatment
) 77 78 128 129 O
with 79 83 130 134 O
documented 84 94 135 145 O
progressive 95 106 146 157 O
disease 107 114 158 165 O
( 115 116 166 167 O
post 116 120 167 171 O
- 120 121 171 172 O
secondary 121 130 172 181 O
hormone 131 138 182 189 O
CRPC 139 143 190 194 B-cancer
) 143 144 194 195 O

For 0 3 196 199 O
biochemically 4 17 200 213 O
relapsed 18 26 214 222 O
patients 27 35 223 231 O
, 35 36 231 232 O
no 37 39 233 235 O
concurrent 40 50 236 246 O
use 51 54 247 250 O
of 55 57 251 253 O
ADT 58 61 254 257 B-treatment
or 62 64 258 260 O
orchiectomy 65 76 261 272 B-treatment
and 77 80 273 276 O
no 81 83 277 279 O
known 84 89 280 285 O
prior 90 95 286 291 O
or 96 98 292 294 O
current 99 106 295 302 O
evidence 107 115 303 311 O
of 116 118 312 314 O
any 119 122 315 318 O
metastatic 123 133 319 329 O
involvement 134 145 330 341 O
of 146 148 342 344 O
distant 149 156 345 352 O
organs 157 163 353 359 O

For 0 3 360 363 O
post 4 8 364 368 O
- 8 9 368 369 O
secondary 9 18 369 378 O
hormone 19 26 379 386 O
patients 27 35 387 395 O
, 35 36 395 396 O
no 37 39 397 399 O
concurrent 40 50 400 410 O
treatment 51 60 411 420 O
with 61 65 421 425 O
a 66 67 426 427 O
secondary 68 77 428 437 O
hormone 78 85 438 445 O
( 86 87 446 447 O
e.g. 87 91 447 451 O
enzalutamide 92 104 452 464 B-treatment
, 104 105 464 465 O
abiraterone 106 117 466 477 B-treatment
) 117 118 477 478 O
, 118 119 478 479 O
no 120 122 480 482 O
metastasis 123 133 483 493 B-cancer
to 134 136 494 496 I-cancer
the 137 140 497 500 I-cancer
liver 141 146 501 506 I-cancer
or 147 149 507 509 I-cancer
brain 150 155 510 515 I-cancer

For 0 3 516 519 O
pre 4 7 520 523 O
- 7 8 523 524 O
secondary 8 17 524 533 O
hormone 18 25 534 541 O
patients 26 34 542 550 O
, 34 35 550 551 O
no 36 38 552 554 O
prior 39 44 555 560 O
or 45 47 561 563 O
concurrent 48 58 564 574 O
treatment 59 68 575 584 B-treatment
with 69 73 585 589 O
a 74 75 590 591 O
secondary 76 85 592 601 O
hormone 86 93 602 609 O
( 94 95 610 611 O
e.g. 95 99 611 615 O
enzalutamide 100 112 616 628 B-treatment
, 112 113 628 629 O
abiraterone 114 125 630 641 B-treatment
) 125 126 641 642 O

Histological 0 12 643 655 O
or 13 15 656 658 O
cytological 16 27 659 670 O
diagnosis 28 37 671 680 O
of 38 40 681 683 O
prostate 41 49 684 692 B-cancer
cancer 50 56 693 699 I-cancer

History 0 7 700 707 O
of 8 10 708 710 O
inflammatory 11 23 711 723 B-chronic_disease
bowel 24 29 724 729 I-chronic_disease
disease 30 37 730 737 I-chronic_disease

History 0 7 738 745 O
of 8 10 746 748 O
or 11 13 749 751 O
active 14 20 752 758 O
autoimmune 21 31 759 769 B-chronic_disease
disorders 32 41 770 779 I-chronic_disease
( 42 43 780 781 O
including 43 52 781 790 O
but 53 56 791 794 O
not 57 60 795 798 O
limited 61 68 799 806 O
to 69 71 807 809 O
: 71 72 809 810 O
myasthenia 73 83 811 821 B-chronic_disease
gravis 84 90 822 828 I-chronic_disease
, 90 91 828 829 O
thyroiditis 92 103 830 841 B-chronic_disease
, 103 104 841 842 O
pneumonitis 105 116 843 854 B-chronic_disease
, 116 117 854 855 O
rheumatoid 118 128 856 866 B-chronic_disease
arthritis 129 138 867 876 I-chronic_disease
, 138 139 876 877 O
multiple 140 148 878 886 B-chronic_disease
sclerosis 149 158 887 896 I-chronic_disease
, 158 159 896 897 O
systemic 160 168 898 906 B-chronic_disease
lupus 169 174 907 912 I-chronic_disease
erythematosus 175 188 913 926 I-chronic_disease
, 188 189 926 927 O
scleroderma 190 201 928 939 B-chronic_disease
) 201 202 939 940 O
and 203 206 941 944 O
other 207 212 945 950 O
conditions 213 223 951 961 O
that 224 228 962 966 O
disorganize 229 240 967 978 O
or 241 243 979 981 O
alter 244 249 982 987 O
the 250 253 988 991 O
immune 254 260 992 998 O
system 261 267 999 1005 O

Hormone 0 7 1006 1013 B-cancer
sensitive 8 17 1014 1023 I-cancer
relapsing 18 27 1024 1033 I-cancer
prostate 28 36 1034 1042 I-cancer
cancer 37 43 1043 1049 I-cancer
after 44 49 1050 1055 O
definitive 50 60 1056 1066 O
local 61 66 1067 1072 B-treatment
therapy 67 74 1073 1080 I-treatment
( 75 76 1081 1082 O
biochemical 76 87 1082 1093 O
relapse 88 95 1094 1101 O
) 95 96 1101 1102 O

Progressive 0 11 1103 1114 O
disease 12 19 1115 1122 O
post 20 24 1123 1127 O
- 24 25 1127 1128 O
surgical 25 33 1128 1136 B-treatment
castration 34 44 1137 1147 I-treatment
or 45 47 1148 1150 O
during 48 54 1151 1157 O
androgen 55 63 1158 1166 B-treatment
suppression 64 75 1167 1178 I-treatment
therapy 76 83 1179 1186 I-treatment
( 84 85 1187 1188 O
pre 85 88 1188 1191 B-cancer
- 88 89 1191 1192 I-cancer
secondary 89 98 1192 1201 I-cancer
hormone 99 106 1202 1209 I-cancer
CRPC 107 111 1210 1214 I-cancer
) 111 112 1214 1215 O

